Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19 †

Background: Immunomodulatory drugs have been used in patients with severe COVID-19. The objective of this study was to evaluate the effects of two different strategies, based either on an interleukin-1 inhibitor, anakinra, or on a JAK inhibitor, such as baricitinib, on the survival of patients hospi...

Descripción completa

Detalles Bibliográficos
Autores principales: García-García, José A, Pérez-Quintana, Marta, Ramos-Giráldez, Consuelo, Cebrián-González, Isabel, Martín-Ponce, María L, del Valle-Villagrán, José, Navarro-Puerto, María A, Sánchez-Villegas, Jorge, Gómez-Herreros, Rocío, Manoja-Bustos, Isabel, León-Martí, Daniel, Serrano-Rodríguez, Lucía, de Miguel-Albarreal, Alejandra, Velasco-Romero, María J, Mula-Falcón, Francisco, Fernández-Pérez, Pilar, Melguizo-Moya, Isabel, Pérez-Quintana, María J, Romero-Molina, Guillermo, Vergara-López, Salvador, Marenco-de la Fuente, José L, Marín-Martín, Jorge, Mira-Escarti, José A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432474/
https://www.ncbi.nlm.nih.gov/pubmed/34501467
http://dx.doi.org/10.3390/jcm10174019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432474/
https://www.ncbi.nlm.nih.gov/pubmed/34501467
http://dx.doi.org/10.3390/jcm10174019

Ejemplares similares